Syntara

Syntara EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Syntara (SNT.AX) as of Oct 17, 2026 is -85.45 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -103.29 % — a change of -17.27% (higher).

EBIT/Assets

-85.45 %

YoY

-17.27%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Syntara is 2026 -85.45 % . Operating Income to Assets Ratio (EBIT/Assets) of Syntara was 2025 -103.29 % . It decreases by -17.27% higher compared to the previous year.

The Syntara EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2019
-36.81 AUD
Jan 1, 2020
-44.84 AUD
Jan 1, 2021
-67.78 AUD
Jan 1, 2022
-78.75 AUD
Jan 1, 2023
-77.79 AUD
Jan 1, 2024
-135.46 AUD
Jan 1, 2025
-103.29 AUD
Jan 1, 2026
-85.45 AUD
The Syntara EBIT/Assets history
YEAREBIT/AssetsYoY
-85.45 %-17.27%
-103.29 %-23.75%
-135.46 %+74.12%
-77.79 %-1.21%
-78.75 %+16.18%
-67.78 %+51.18%
-44.84 %+21.79%
-36.81 %-364.11%
13.94 %-135.73%
-39.01 %+36.65%
-28.55 %-245.99%
19.55 %-136.63%
-53.38 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Syntara Stock analysis

What does Syntara do? Syntara Ltd, headquartered in Frenchs Forest, New South Wales, operates in the Pharmaceuticals sector within the Health Care industry. Listed on 10 November 2003, the company focuses on developing clinical-stage drugs for blood-related cancers, including myelofibrosis, with its lead candidate PXS-5505. Syntara also advances pan-LOX inhibitors for scar prevention and PXS-4728 for sleep disorders and neurodegenerative diseases. Additional drug candidates target fibrotic and inflammatory conditions such as kidney fibrosis and NASH, alongside respiratory products Bronchitol and Aridol for cystic fibrosis and lung function testing. Syntara is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Syntara stock

Operating Income to Assets Ratio (EBIT/Assets) of Syntara is -85.45 % in 2026.

Operating Income to Assets Ratio (EBIT/Assets) of Syntara changed from -103.29 % to -85.45 %, representing a -17.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Syntara since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Syntara with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Syntara

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Syntara